

Special Issue

Feature Papers in Section “Methods and Technologies Development” in 2026

Message from the Guest Editor

We are excited to present the Special Issue from *Cancers*: “Feature Papers in Section “Methods and Technologies Development” in 2026”. As we move further into the era of digital medicine, technologies like artificial intelligence and high-precision biomarkers (e.g., genetic, protein-based or liquid biopsies) are revolutionizing clinical diagnostics, image acquisition and therapy response prediction. This edition describes the intersection of technology and oncology. Our goal is to highlight the milestone achievements of multidisciplinary teams and provide a roadmap for the next generation of cancer diagnostics and treatment.

Guest Editor

Prof. Dr. Maxim V. Berezovski
Department of Chemistry and Biomolecular Sciences, University of
Ottawa, Ottawa, ON K1N 6N5, Canada

Deadline for manuscript submissions

1 March 2027



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/272651

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)